Muttenz, Switzerland, 16 September 2021 – Opterion Health AG, a nephrology company focused on innovation in Peritoneal Dialysis (PD), today announced a significant strengthening of its management team, including the appointments of Daniel Lustenberger as Chief Financial Officer (CFO) and Peter Reinemer as Chief Technology Officer (CTO). Mylène Fleurant has been appointed Head of Quality and Ulrike Grimm Head of Project Management. Andreas Schmidt, whom Daniel Lustenberger succeeds as CFO, will continue to support Opterion Health as a partner.
Peritoneal Dialysis Patients
News & Press Releases
15 July 2021 – It’s been about 100 days since Englund, Björn joined Opterion Health AG as CEO. With his broad background in the dialysis business, how has he experienced his start with Opterion? “The last 100 days have been awesome! Our drive for innovation at Opterion and the novel solution for peritoneal dialysis (PD) we are developing will be a real game changer in dialysis and, more importantly, will improve patients’ quality of life once
3 June 2021 – Hello The 5th Floor – hello Muttenz, Baselland! Opterion Health AG has just moved into its new offices and is excited to become part of the innovative life sciences ecosystem around Basel. The new offices, next to the recently launched inQbator – a startup accelerator created through a partnership between BLKB, HEMEX and Launchpad – and other innovative companies are inspiring and will help us advance our goal to bring innovation
25 March 2021 – Opterion Health AG, a preclinical Swiss life science company, developing the first novel solution for peritoneal dialysis (PD) in the last two decades, today announced the appointment of Björn Englund as CEO. He will take over this role in April 2021, succeeding Guido Grentzmann, the founder and CSO of Opterion, who will focus his activities on the scientific development of the company and the preparation of the start of Phase I.
9 March 2021 – Guido Grentzmann, CEO and CSO of Opterion Health AG, shared insights on our new osmotic driver for Peritoneal Dialysis (PD) at the recent virtual ISPD (International Society for Peritoneal Dialysis)-EuroPD Joint Conference: Common PD fluids use glucose as osmotic driver (ODR) at concentrations between 1% and 5%. The high glucose concentration of conventional PD fluids leads to high initial osmotic pressure. The back-diffusion of glucose, from the dialysate into the patient’s bloodstream, presents a
17 February 2021 – Our portfolio company Opterion Health AG seeks to enhance the quality of life for patients with end-stage renal disease (ESRD) and their loved ones, and to increase survival rates of ESRD patients. They launched their new website at the beginning of the year and have very exciting plans for 2021! Chronic kidney disease is the progressive loss of kidney function. When it reaches an advanced state, end-stage renal disease (ESRD) appears. During
17 February 2021 – Thank you HEMEX for this contribution, excellent support and trust in our novel Peritoneal Dialysis (PD) solution! Our goal is to bring innovation to dialysis care and promote home dialysis to improve the quality of life for patients as well as their families. Preclinical activities and preparations for phase I are in full swing.
12 February 2021 – Amelie Tsoutsoulopoulos and Guido Grentzmann from Opterion Health AG are participating at the virtual ISPD (International Society for Peritoneal Dialysis) – EuroPD Joint Conference. Meet the Opterion team at the oral presentation ‘Osmotically active composition for peritoneal Dialysis’, taking place Monday, 1st March 2021, from 18:15 – 19:45 (CET) / 17:15 – 18:45 (UTC) / 12:15 – 13:45 (ET) in the ‘Free Communications – Basic Science’ session.
6 February 2021 – “About 40% of dialysis incidence is due to diabetes. Further, in times of a pandemic, as we are currently experiencing, an increasing number of patients are reluctant to visit a clinic or a hospital,” says Guido Grentzmann, the founder and CEO/CSO of Opterion Health AG. “Therefore, a physiological glucose or glucose-free peritoneal dialysis (PD) solution, which Opterion has in pre-clinical development, is a much-needed innovation, not only for diabetic dialysis patients, but
26 January 2021 – The entire Opterion Health AG team is excited to move to ‹The 5th Floor› in Muttenz, Basel-Landschaft, and benefit from the innovative life sciences ecosystem around Basel. A big thank you to the ‹Basel Area Business & Innovation› team for their excellent support.
22 January 2021 – Opterion is moving from the canton of Obwalden to Muttenz in the canton of Basel-Landschaft in order to benefit from the local life sciences ecosystem. Following a significantly oversubscribed bridge financing round, Opterion was able to raise a total of 8.4 million euros for its innovative peritoneal dialysis solution. Opterion Health AG has announced its intention to vacate its current headquarters in Sarnen in the canton of Obwalden and move to
19 January 2021 – Opterion Health AG, a preclinical Swiss life science company, developing the first novel solution for peritoneal dialysis (PD) in the last two decades, today announced the successful agreement of a EUR 8.4m Bridge Financing Round. This amount was exclusively raised from a limited number of professional private and institutional investors based in Switzerland and Germany. The proceeds from this financing round will be used to complete preclinical activities and prepare for entry into Phase I.